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Hexosamine biosynthetic pathway (HBP) accounts for some cardio-
vascular adverse effects of hyperglycemia. We investigated whether
the HBP inhibitor azaserine protects against hyperglycemia-induced
endothelial damage dependently of HBP. Human endothelial cells
isolated from umbilical veins were exposed either to a high (30.5
mmol/l) or low concentration of glucose (5.5 mmol/l) for 4 days,
followed by a stimulation with TNF- (1 ng/ml, 24 h). The blockade
of the rate-limiting enzyme glutamine:fructose-6-phosphate amido-
transferase inhibited HBP ﬂux and oxidative stress (generation of
superoxide and peroxynitrite) under the hyperglycemic condition and
prevented the synergistic stimulation of VCAM-1 and ICAM-1 ex-
pression by hyperglycemia and TNF-. In the cells cultured under a
low-glucose condition when no increased HBP ﬂux occurred, azaser-
ine enhanced the manganese-superoxide dismutase (MnSOD) protein
level and also inhibited the oxidative stress and the expression of
VCAM-1 and ICAM-1 in response to TNF-. Moreover, the poly-
phenol resveratrol inhibited the oxidative stress and adhesion mole-
cule expression and did not decrease the HBP ﬂux under the hyper-
glycemia condition. In addition, in isolated rat aortas exposed to
hyperglycemic buffer for 5 h when no signiﬁcant HBP ﬂux occurred,
azaserine upregulated the MnSOD protein level and prevented de-
creased endothelium-dependent relaxations to acetylcholine. In con-
clusion, hyperglycemia independently increases oxidative stress and
HBP ﬂux, ampliﬁes endothelial inﬂammation, and impairs endothelial
function mainly through oxidative stress and not the HBP pathway.
Azaserine protects against hyperglycemic endothelial damage through
its antioxidant effect independently of inhibiting HBP pathway.
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DIABETES MELLITUS is highly associated with an increased risk of
cardiovascular morbidity and mortality (10, 34). Chronic hy-
perglycemia causes glucotoxicity to vascular cells, particularly
the endothelial cells, resulting in an increased incidence of
cardiovascular events (7). Clinical and experimental studies
provide compelling evidence showing that hyperglycemia is
associated with impaired endothelium-dependent relaxations
(7) and increased endothelial expression of adhesion mole-
cules, vascular cell adhesion molecule-1 (VCAM-1), and in-
tercellular adhesion molecule-1 (ICAM-1) (20, 31). The de-
creased endothelial nitric oxide (NO) synthase (eNOS) func-
tion and upregulation of the adhesion molecules enhance the
adhesion of inﬂammatory cells onto the endothelium followed
by a transmigration of the cells into the subendothelial space,
a key early process in atherogenesis (15). Numerous proin-
ﬂammatory cytokines such as tumor necrosis factor- (TNF-
), interleukins, etc., are found to be increased in obesity and
obesity-associated metabolic disorders (24). This proinﬂam-
matory status causes vascular endothelial inﬂammation, i.e., an
increased expression of VCAM-1 and ICAM-1 (32). It is
conceivable that hyperglycemia and proinﬂammatory cyto-
kines, e.g., TNF-, work in concert to accelerate the vascular
endothelial damage, leading to cardiovascular disease.
There is overwhelming evidence demonstrating that hyper-
glycemia produces superoxide from various sources including
mitochondrion, NADPH oxidase, and eNOS uncoupling,
which plays a central role in endothelial damage (4, 7, 30), The
increased oxidative stress may be the causal link between
various pathways/mechanisms of hyperglycemic endothelial
dysfunction. Among them, the increased ﬂux of hexosamine
biosynthetic pathway (HBP), which shunts excessive intracel-
lular glucose into the biosynthesis of UDP-N-acetylglu-
cosamine (UDP-GlcNAc), has attracted much attention be-
cause of its properties to interfere with various cellular func-
tions, including signal transductions, transcriptional activity,
cell proliferation, apoptosis, and proteasomal degradation (1,
13, 22). In the HBP pathway, glucose under the sustained
hyperglycemic condition is taken up by the cells via glucose
transporters and converted to glucosamine-6-phosphate by the
rate-limiting enzyme L-glutamine:D-fructose-6-phosphate amido-
transferase (GFAT). Glucosamine-6-phosphate is further me-
tabolized to UDP-GlcNAc that serves as the major substrate for
the formation of O-linked glycoproteins (O-GlcNAc) at serine
and threonine residues catalyzed by O-glycosyltransferase. The
increased GFAT activity and O-GlcNAc levels are implicated
in insulin resistance and type II diabetes mellitus (16, 37),
associated with increased oxidative stress and, reciprocally,
with Akt/eNOS phosphorylation in the endothelial cells, result-
ing in a decreased endothelial NO production (11, 13, 27).
Although the increased HBP ﬂux may explain at least in part
the decreased eNOS activity, it is, however, not known
whether it is involved in endothelial inﬂammation under the
hyperglycemic condition. The relationship between the HBP
pathway and oxidative stress seems obscure. It has been
reported that oxidative stress stimulates the HBP pathway on
one hand (4) and that the HBP pathway is also able to induce
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oxidative stress on the other hand (19, 36). Moreover, azaser-
ine is frequently used as an inhibitor of the HBP pathway to
delineate its functional roles based on the effect of the com-
pound on cellular O-GlcNAc levels. Whether azaserine, like
any other chemical substances, could affect cellular functions
independently of the HBP pathway is not known. The present
study is aimed to investigate the roles of oxidative stress and
the HBP pathway in a high glucose (HG)-induced ampliﬁca-
tion of endothelial inﬂammatory responses and endothelial
damage. The pharmacological mechanisms of azaserine on
endothelial protection under the hyperglycemic condition were
investigated.
MATERIALS AND METHODS
Reagents and antibodies. All chemicals, including those for immu-
noblotting, were obtained from Sigma (Buchs, Switzerland), unless
otherwise indicated: L-norepinephrine bitartrate and acetylcholine.
TNF- was purchased from R&D Systems; dihydroethidium (DHE)
and MitoSox were purchased from Invitrogen (Lucerne, Switzerland);
antibodies against ICAM-1 and VCAM-1 were from Santa Cruz
Biotechnology (Munningen, Switzerland); anti-nitrotyrosine antibody
was from Upstate Biotechnol (Luzernachem, Luzern, Switzerland);
anti-MnSOD antibody was from Abcam (Cambridge, UK); CTD110.6
antibody was a kind gift from Dr. Gerald W. Hart (The Johns Hopkins
University School of Medicine, Baltimore, Maryland); biotin-labeled
anti-mouse IgM was purchased from Sigma; Alexa ﬂuor 680-conju-
gated streptavidin was from Invitrogen; anti-O-linked N-acetylglu-
cosamine (RL2) antibody was from Afﬁnity Bioreagents (Lucerne,
Switzerland), IRDye 800-conjugated afﬁnity puriﬁed goat anti-rabbit
IgG Fc was purchased from BioConcept (Allschwil, Switzerland);
Alexa ﬂuor 680-conjugated goat anti-mouse IgG (H  L) was from
Invitrogen. Endothelial cell growth supplement pack was from Pro-
moCell (Allschwil, Switzerland), and all cell culture media and
materials were purchased from GIBCO (Lucerne, Switzerland).
Endothelial cell culture. Endothelial cells were isolated from hu-
man umbilical veins and characterized as described in the study of
Ming et al. (26). Cells from the second to fourth passages were used.
The endothelial cells were cultured in low-glucose (LG, 5.5 mmol/l)
or HG (30.5 mmol/l) DMEM supplemented with 5% FCS, endothelial
cell growth supplement, and 0.6 nmol/l insulin for 4 days. The cells
were then cultured in the same medium, however, supplemented with
1% FCS for 5 h followed by the stimulation with TNF- (1 ng/ml) for
24 h. To test whether changes in osmolality could contribute to
endothelial responses under the HG condition, 25 mmol/l mannitol
were included in the LG medium (5.5 mmol/l). For some experiments,
the cells were incubated with azaserine (0.2 to 1 mol/l) or resveratrol
(10 mol/l) throughout the experiments. The same amount of DMSO
(used to dissolve resveratrol) was added to the control cells.
Animals. The experimental protocols with animals were approved
by the Federal Veterinary Ofﬁce of Switzerland (Nr. 174/07). Wistar-
Kyoto male rats (3 mo, Harlan) were fed normal chow and maintained
according to the local rules of animal experimentation. The animals
were anesthetized with pentobarbital sodium (50 mg/kg body wt ip)
and euthanized. The aortas were removed and cleaned of perivascular
fat tissues and prepared for organ chamber experiments.
Endothelium-dependent and -independent relaxations. The aortic
rings (3 mm in length) with intact endothelium were prepared as
previously described (25). They were suspended in a modiﬁed Krebs-
Ringer bicarbonate solution containing (in mmol/l) 118 NaCl, 4.7
KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 0.026 EDTA,
and 5.5 glucose, aerated with 95% O2-5% CO2 at 37°C in a Multi-
Myograph System (Model 610M, Danish Myo Technology). One ring
served as a control; the second ring was incubated in Krebs buffer
containing 25 mmol/l D-glucose for 5 h, and the third ring in the HG
buffer but with 1 mol/l azaserine. The aortic rings were contracted
with norepinephrine (0.3 mol/l). Endothelium-dependent relaxations
were examined with acetylcholine. At the end of the experiments, the
aortic rings were snap frozen in liquid nitrogen and kept in 80°C
until use.
ICAM-1 and VCAM-1 protein expression and O-linked glycosyla-
tion. Cell lysate preparation, 8% SDS-PAGE, and protein transfer
from SDS-PAGE gels to an Immobilon-P membrane (Millipore) were
performed as previously described (26). The resultant membranes
were ﬁrst incubated with the individual primary antibody at room
temperature for 2 to 3 h after blocking with 5% skimmed milk. The
blots were then incubated with a corresponding anti-mouse (Alexa
ﬂuor 680 conjugated) or anti-rabbit (IRDye 800 conjugated) second-
ary antibody (1:5,000) for 2 h, and the quantiﬁcation of the signals
was performed using the Odyssey Application Software 1.2.
For analysis of the O-GlcNAc level, the same experimental proce-
dure as described above was used, except that the membranes were
ﬁrst incubated with the mouse antibody against O-GlcNAc (RL2) at a
dilution of 1:1,000 for 2 to 3 h. Alternatively, the membranes were
incubated with the antibody CTD110.6 (mouse IgM) at a dilution of
1:2,500 for 2 h after 1 h blocking with 3% bovine serum albumin/
Tris-buffered saline  0.05% Tween-20 (BSA/TBST) at room tem-
perature according to the described protocol (6) with slight modiﬁca-
tions. The blots were washed three times for 10 min with the TBST,
followed by an incubation with biotin-labeled anti-mouse IgM as a
secondary antibody (1:10,000). After being washed three times with
TBST, the blots were ﬁnally incubated with Alexa ﬂuor 680-conju-
gated streptavidin (1:5,000) for 1 h. The signals were visualized using
Odyssey Infrared Imaging System (LI-COR Biosciences, Bad Hom-
burg, Germany). In another series of experiments, aortic tissues were
homogenized in ice-cold extraction buffer containing (in mmol/l) 120
NaCl, 50 Tris (pH 8.0), 20 NaF, 1 benzamidine, 1 EDTA, 1 EGTA,
1 sodium pyrophosphate, 30 4-nitrophenyl phosphate disodium salt
hexahydrate, 1% Nonidet P-40, and 100 phenylmethylsulfonyl ﬂuo-
ride (PMSF) for immunoblotting to detect O-GlcNAc levels as de-
scribed above.
DHE and MitoSox staining for superoxide anion generation. The
endothelial cells were incubated either with 5.0 mol/l of DHE for 20
min or with MitoSox (5 mol/l) for 10 min followed by TNF- (1
ng/ml) stimulation for 10 min as described (40). Images were obtained
with Zeiss ﬂuorescence microscopy. The intensity of the ﬂuorescence
was quantiﬁed by ImageJ software (Leica).
Confocal microscopy for immunostaining of 3-nitrotyrosine. Endo-
thelial cells were cultured on coverslips as described for 4 days under
the LG and HG condition, respectively, followed by TNF- stimula-
tion (1 ng/ml, 24 h). The cells were ﬁxed in 4% paraformaldehyde for
40 min at room temperature. After being rinsed with PBS for 5 min,
the cells were permeabilized with 0.3% Triton-X/PBS for 10 min at
room temperature. The cells were rinsed three times for 5 min in PBS,
followed by the blocking of nonspeciﬁc antigens with 2% BSA-PBS
for 30 min at room temperature. The cells were then incubated with
the anti-nitrotyrosine antibody (1:50) in PBS containing 10% goat
serum for 2 h at room temperature. The cells were washed three times
for 5 min in PBS and then incubated with Alexa ﬂuor 594-conjugated
goat anti-rabbit secondary antibody (1:400) for 1 h at room temper-
ature. After three times of being rinsed for 5 min, the cells were
incubated with 4,6-diamidino-2-phenylindole for 2 min to stain the
nuclei. The cells were ﬁnally washed with PBS three times for 5 min
and mounted with anti-fading Vectashield and sealed with nail polish.
The sections were then observed for immunoﬂuorescence under a
LEICA SP5 confocal microscope. Pictures were taken with a 63
objective.
FACS analysis of peroxynitrite formation. Endothelial cells were
cultured as described for 5 days under the LG and HG condition,
respectively. Subsequently, the cells were collected by trypsinization,
ﬁxed in 4% paraformaldehyde, and stained for 3-nitrotyrosine as
described in Confocal microscopy for immunostaining of 3-nitroty-











ments were performed using FACS caliber system (PARTEC). Nitroty-
rosine was excited by laser at 488 nm, and the data were collected at
590 nm (FL2) channels. Twenty thousand events were measured, and
the data were analyzed by WinMDI software and presented by
histogram as the fold increase in the counts of nitrotyrosine positive
cells in the different samples.
Statistical analysis. All data were given as means  SE. The
ANOVA with Bonferroni post hoc test was used for statistical anal-
ysis. A two-tailed value of P  0.05 was considered to indicate a
statistically signiﬁcant difference.
RESULTS
Azaserine inhibits endothelial inﬂammation induced by HG/
TNF-. The incubation of the endothelial cells to a HG con-
centration (30.5 mmol/l) for 5 days to mimic chronic hyper-
glycemia did not signiﬁcantly affect the basal protein level of
VCAM-1 or ICAM-1 compared with those of the cells cultured
at the LG concentration (5.5 mmol/l, Fig. 1, A and B; n 	 5);
it however, markedly enhanced the stimulating effects of
TNF- (1 ng/ml, 24 h) on both VCAM-1 and ICAM-1 expres-
sion in the cells (Fig. 1, A and B; 2.2- and 2.5-fold, respec-
tively, P  0.001 vs. LG  TNF-, n 	 5). In contrast to
glucose, the incubation of the cells with mannitol (25 mmol/l)
in 5.5 mmol/l LG medium, to match the osmolality of HG
medium, had no potentiating effects on the TNF--stimulated
levels of VCAM-1 and ICAM-1 (supplemental Fig. 1; note: all
supplemental ﬁgures may be found posted with the online
version of this article).
In parallel, HG (30.5 mmol/l, 5 days) enhanced the O-
GlcNAc modiﬁcation of various cellular proteins with molec-
ular mass ranging from 115 to 200 kDa (supplemental Fig. 2;
n 	 4). The level of protein O-GlcNAc was not affected by
TNF- (supplemental Fig. 2; n 	 4). In the presence of the
GFAT inhibitor azaserine (0.2 to 1 mol/l), the HG-induced
O-GlcNAc was signiﬁcantly reduced (Fig. 2; n 	 5), and the
protein levels of both VCAM-1 and ICAM-1 stimulated by
TNF- (1 ng/ml, 24 h) under the HG (30.5 mmol/l) condition
were also strongly inhibited by azaserine (0.2 to 1 mol/l, Fig. 3;
n 	 5, P  0.01–0.001 vs. HG  TNF-). Similar inhibitory
effects of azaserine were also observed in cells treated with
TNF- (1 ng/ml, 24 h) under the LG (5.5 mmol/l) condition
(Fig. 4; n 	 5, P  0.01–0.001 vs. TNF- alone), where the
level of protein O-GlcNAc was not affected (supplemental Fig.
3B; n 	 3). The results suggest that azaserine inhibits endo-
thelial VCAM-1 and ICAM-1 expression through HBP-inde-
pendent mechanism(s).
Azaserine inhibits endothelial inﬂammation through antiox-
idant effects. Superoxide anion generation measured by ﬂuo-
rescence density of DHE staining was increased in the endo-
thelial cells exposed to HG (30.5 mmol/l, 5 days) medium or
TNF- alone (1 ng/ml, 10 min) and was signiﬁcantly enhanced
when the cells were stimulated by both HG and TNF-
together (Fig. 5, A and B). This effect was prevented by
azaserine (0.2 to 1 mol/l, Fig. 5, A and B; n 	 3, P 
0.01–0.001 vs. HG  TNF-). The antioxidant effect of
azaserine was also observed in cells stimulated by TNF- (1
Fig. 1. High glucose (HG) ampliﬁes endothelial adhesion molecule expression
to TNF-. A: HG (30.5 mmol/l, 5 days) alone did not signiﬁcantly affect
VCAM-1 and ICAM-1 expression in the endothelial cells, however, but
markedly enhanced the effects of TNF- (1 ng/ml) on the cell adhesion
molecule expression (n	 5 sets of experiments). B: quantiﬁcation of the above
results. *P  0.001 vs. low glucose (LG); #P  0.05 vs. LG  TNF-.
Fig. 2. Azaserine inhibits HG-induced O-GlcNAc levels. The increased pro-
tein O-GlcNAc levels under the HG (30.5 mmol/l, 5 days) condition were
inhibited by azaserine (0.2 to 1.0 mol/l). This experiment was repeated 5











ng/ml, 10 min) under the LG condition (supplemental Fig. 3A;
n 	 3) when no increased O-GlcNAc occurred (supplemental
Fig. 3B; n 	 3). The superoxide anion generation measured by
ﬂuorescence density of MitoSox staining was increased in the
endothelial cells exposed to HG (30.5 mmol/l, 5 days) medium,
and TNF- did not further enhance the MitoSox signal. Aza-
serine (1 mol/l) was able to inhibit mitochondrial superoxide
generation in cells stimulated by HG plus TNF- (supplemen-
tal Fig. 4; P  0.001, n 	 4).
Furthermore, an enhanced peroxynitrite formation (cellular
3-nitrotyrosine level) as detected by the confocal microscope
was observed under the HG condition or TNF- stimulation
and further increased when the cells were stimulated by HG
and TNF- together (Fig. 6A; n 	 4). Quantitative FACS
analysis showed an increased peroxynitrite production in cells
under the HG condition, which was further enhanced by
TNF- (Fig. 6, B and C; n 	 4). The stimulation of peroxyni-
trite formation was fully blocked in the presence of azaserine
(Fig. 6, B and C; n 	 4). The results together with those on
O-GlcNAc obtained under the LG condition suggest that aza-
serine inhibits endothelial inﬂammation through antioxidant
effects rather than through the inhibition of O-GlcNAc synthe-
sis. Moreover, the antioxidant polyphenol resveratrol (10
mol/l) reduced the upregulation of VCAM-1 and ICAM-1 by
HG (30.5 mol/l) and TNF- (1 ng/ml, 24 h) (supplemental Fig.
5; n	 4, P 0.01 vs. HG TNF-) and inhibited superoxide
anion generation in parallel (supplemental Fig. 6; n 	 4) but
did not decrease the O-GlcNAc protein level as detected by the
two different antibodies (RL2 or CTD110.6) for O-GlcNAc
(supplemental Fig. 7, A and B; n 	 3).
Interestingly, the protein level of the antioxidant enzyme
manganese-superoxide dismutase (MnSOD) was markedly up-
regulated by azaserine (1 mol/l, 5 days) in the endothelial
cells under the LG condition (Fig. 7, A and B, lane 2, 10-fold
increase; n 	 4, P  0.001 vs. LG). TNF- (1 ng/ml, 24 h)
under the LG condition was also able to upregulate the MnSOD
level (Fig. 7, A and B, lane 3, n 	 4, P  0.001 vs. LG alone),
whereas HG had no signiﬁcant effect on MnSOD expression
(Fig. 7, A and B, lane 5, n 	 4). Interestingly, the effect of
TNF- on MnSOD upregulation was abolished under the HG
condition (Fig. 7, A and B, lane 7). Of particular importance is
the observation that the suppressing effect of TNF- plus HG
on MnSOD (lane 7) was prevented by azaserine (1 mol/l, 5
days, Fig. 7, A and B, lane 8; n 	 4, P  0.001 vs. lane 7).
Moreover, a short-time (1 h) treatment of the cells with
azaserine (1 mol/l) already signiﬁcantly upregulated MnSOD
expression under the LG condition, although this acute effect is
much weaker (1.8-fold increase, supplemental Fig. 8) than the
chronic effect. It is noteworthy that TNF- also acutely up-
regulated MnSOD in the endothelial cells and that the MnSOD
level remained high in the presence of both TNF- and
azaserine (supplemental Fig. 8). The superoxide generation
stimulated by TNF- (1 ng/ml, 30 min) under the LG condition
was abolished by a 1-h treatment of the cells with azaserine (1
mol/l) (supplemental Fig. 9; n 	 4; P  0.05 vs. TNF-).
Azaserine prevents HG-induced impairment of endothelium-
dependent relaxations. In another series of experiments with
isolated Wister-Kyoto rat aortic rings with endothelium con-
tracted with norepinephrine (0.3 mol/l), the incubation of the
blood vessels with 25 mmol/l of glucose for 5 h signiﬁcantly
impaired endothelium-dependent relaxations in response to
Fig. 4. Azaserine inhibits endothelial adhesion molecule expression under LG
conditions. A: TNF--stimulated expression of VCAM-1 and ICAM-1 under
LG (5.5 mmol/l) was inhibited by azaserine (n 	 5 sets of experiments).
B: quantiﬁcation of the above results. *P  0.01 and **P  0.001 vs. TNF-
alone.
Fig. 3. Azaserine inhibits endothelial adhesion molecule expression under HG
condition. A: TNF--stimulated expression of VCAM-1 and ICAM-1 under
HG (30.5 mmol/l) was inhibited by azaserine (n 	 5 sets of experiments).












acetylcholine (1 nmol/l to 10 mol/l) (Fig. 8A; n 	 5). This
deleterious effect of hyperglycemia on endothelium-dependent
relaxations was reversed in the presence of the GFAT inhibitor
azaserine (10 mol/l, n 	 5, P  0.001 to 0.05 vs. glucose,
Fig. 8A). Under the 5-h short-time incubation of aortas in HG
buffer, no signiﬁcant changes in the O-GlcNAc levels in the
aortic tissues were observed (Fig. 8B, and supplemental Fig.
10; n 	 4). Interestingly, in the aortic rings treated with
azaserine, the protein level of MnSOD was signiﬁcantly in-
creased (Fig. 8C; n 	 3, P  0.01 vs. HG).
DISCUSSION
Hyperglycemia is proinﬂammatory and interacts with other
inﬂammatory cytokines. The ampliﬁcation of the proathero-
genic effects in endothelial cells by hyperglycemia has been
reported with C-reactive protein (9, 38). Our present study
further demonstrates that HG ampliﬁes inﬂammatory responses
of the endothelial cells to the cytokine TNF-. The cells
exposed to a HG concentration have no signiﬁcant effects on
the expression of VCAM-1 and ICAM-1 but remarkably en-
hance the stimulating effects of TNF-. The amplifying effects
of HG on the proinﬂammatory cytokines may facilitate vascu-
lar damage, contributing to the higher clinical adverse out-
comes in diabetic patients with inﬂammatory markers (33).
Studies from other groups showed a signiﬁcant increased
expression of the adhesion molecules by HG exposure in
cultured human umbilical vein endothelial cells and human
coronary artery endothelial cells (2, 18, 29), which is slightly
different from the results of our present study. We show only
a weak but not signiﬁcant increase in the expression of
ICAM-1 and VCAM-1 by HG (e.g., Fig. 1, or supplemental
Fig. 4). This slightly different discrepancy might be due to the
different experimental conditions. For example, in the study by
Altannavch et al. (2), the cells were stimulated by the HG
medium containing 20% serum. An interaction of HG and
serum factors in the stimulation of adhesion molecule expres-
sion most likely exists. In other studies (18, 29, 31), no
information is available on how much serum was included in
the HG medium for the cells. In contrast, in our current study,
the cells were exposed to HG medium containing a very low
serum concentration (1% FCS) to avoid a possible strong
interaction between HG and serum factors for the stimulation
Fig. 5. Azaserine inhibits superoxide generation. A: superoxide generation in
human umbilical vein endothelial cells stimulated by TNF- (1 ng/ml, 10 min)
was enhanced under HG condition, which was signiﬁcantly inhibited by
azaserine (0.2 to 1 mol/l; n 	 3 sets of experiments). B: quantiﬁcation of the
above results. DHE, dihydroethidium. *P  0.05 and **P  0.001.
Fig. 6. Azaserine (AZA) inhibits peroxynitrite formation.
A: confocal microscopy and FACS analysis (B and C) demon-
strate peroxynitrite generation (3-nitrotyrosine formation) in the
endothelial cells stimulated by TNF-, HG, or both together











of endothelial adhesion molecule expression while maintaining
the cells in a viable but inactivated situation for 5 days. Our
data do not show a signiﬁcant increase in the endothelial
expression of the adhesion molecules but demonstrate a poten-
tiating effect on TNF--induced VCAM-1 and ICAM-1 ex-
pression. Our in vitro experimental results are in line with the
clinical observations showing the synergistic effects of hyper-
glycemia and inﬂammation in clinical outcomes of patients
with acute coronary syndromes (9, 33, 38).
The vascular endothelial cell damage caused by hypergly-
cemia involves metabolic dysfunctions in the cells and oxida-
tive stress (4, 28). Among these mechanisms, the increased
HBP ﬂux has been reported to account for many of the adverse
effects observed in diabetes mellitus, including insulin resis-
tance and diabetic vascular complications (16). For example,
hyperglycemia induces the O-GlcNAc modiﬁcation of tran-
scription factor Sp1 and increases its activity in aortic endo-
thelial cells, resulting in an enhanced transcription of trans-
forming growth factor-
1 and plasminogen activator inhibi-
tor-1. Elevated O-GlcNAc levels have been observed in
coronary endothelial cells under the HG condition and in
atherosclerotic plaques from humans with diabetes compared
with humans without diabetes (13). eNOS activity in cultured
human coronary and bovine endothelial cells is inhibited by
hyperglycemia through the O-GlcNAc modiﬁcation and the
reciprocal reduction in phosphorylation at Ser1177, contribut-
ing to a reduced endothelial-dependent vasodilatation in dia-
betic patients. Indeed, Musicki et al. (27) demonstrated that
diabetes-related erectile dysfunction is associated with a hy-
perglycemia-induced O-GlcNAc modiﬁcation of eNOS (27).
In accordance, we show in the current study that HG increases
O-GlcNAc levels in the endothelial cells. However, the in-
creased O-GlcNAc does not seem to account for the amplifying
effect of HG on the TNF--induced expression of VCAM-1
and ICAM-1. These conclusions are based on the following
results. First, O-GlcNAc levels induced by HG are not inﬂu-
enced by TNF-. Second, although the GFAT inhibitor aza-
serine reduces O-GlcNAc levels under the HG condition and
inhibits VCAM-1 and ICAM-1 expression, these effects of
azaserine are also observed when the cells are stimulated with
TNF- under the LG condition, at which no obvious increase
in protein modiﬁcation of O-GlcNAc occurs. The results sug-
gest that azaserine inhibits VCAM-1 and ICAM-1 expression
mainly through mechanisms that are most likely independent
of protein O-GlcNAc.
It is well known that oxidative stress plays an important role
in endothelial dysfunction under a HG condition, which ap-
pears to be the crucial mechanism for the pathogenesis of
diabetic vascular complications (3, 30). Numerous studies
demonstrate that a hyperglycemia-induced superoxide genera-
tion can derive from multiple sources in endothelial cells,
including mitochondrion, xanthine oxidase, NAD(P)H-oxi-
dase, cyclooxygenase, and uncoupled eNOS (14). The super-
oxide anion reacts with NO, resulting in a peroxynitrite gen-
eration that is a more potent oxidant causing further oxidative
damage to the cells (14). There is compelling evidence from
recent studies showing that the mitochondrial superoxide gen-
Fig. 7. Effects of azaserine on MnSOD expression in the endothelial cells:
A: chronic effects of azaserine: TNF- (lane 3) not HG (lane 5) upregulates
MnSOD expression. The effect of TNF- is abolished by HG (lane 7). The
downregulation of MnSOD by TNF- under HG condition (lane 7) is reversed
by azaserine (lane 8). Treatment of cells with azaserine upregulates MnSOD
protein level under LG condition (lane 2). B: quantiﬁcation of the above results
(n 	 4 sets of experiments). ***P  0.001.
Fig. 8. Azaserine prevents hyperglycemia-induced
impairment of endothelium-dependent relaxations.
A: incubation of rat aortas with 25 mmol/l glucose in
Krebs buffer for 5 h decreased the endothelium-
dependent relaxations to acetylcholine (n 	 5 rats),
which was prevented in the presence of azaserine (1
mol/l). *P  0.05, **P  0.01, and ***P  0.005
vs. control (5.5 mmol/l glucose). B: no changes in
O-linked N-acetylglucosamine (O-GlcNAc) levels
were observed in the aortas under the condition of
short-term incubation in HG buffer (n	 4 rats). RL2,
antibody against O-GlcNAc. C: MnSOD protein level
was signiﬁcantly increased in aortas treated with aza-











eration plays a major role in oxidative stress under the hyper-
glycemic condition (23, 28, 29, 31). The mitochondrial super-
oxide generation has been demonstrated to mediate the upregu-
lation of endothelial adhesion molecule expression (31) and
has been shown to be prevented by polyphenol resveratrol (23).
With MitoSox as the mitochondrial reactive oxygen species
(ROS) indicator, we also show that HG generates superoxide
from the mitochondrion that is inhibited by azaserine (supple-
mental Fig. 4). TNF- does not further enhance the MitoSox
signal, suggesting that TNF-, in contrast to glucose, stimu-
lates superoxide production mainly from other sources than
from the mitochondrion. Indeed, studies from other groups
demonstrate much higher ROS production from sources other
than the mitochondrion in response to TNF- in the endothelial
cells (8). The results from these studies, however, do not
exclude the role of the other sources of ROS generation that is
stimulated by HG. Moreover, nitrotyrosine formation, the foot-
print of peroxynitrite resulting from reaction of superoxide
anion and NO derived either from uncoupled eNOS or induc-
ible NO synthase (31), is also increased in the cells exposed to
HG and further enhanced by TNF- (Fig. 6), demonstrating the
interaction of HG and TNF- in oxidative stress. Interestingly,
the effects of HG and TNF- on both superoxide generation
and nitrotyrosine formation, as well as the endothelial expres-
sion of adhesion molecules, are inhibited by azaserine, dem-
onstrating that azaserine inhibits ICAM-1 and VCAM-1 ex-
pression via the inhibition of oxidative stress rather than the
inhibition of the HBP pathway. This conclusion is further
supported by the fact that the polyphenol resveratrol that has
been shown to exert antioxidant effects (21) inhibits superoxide
generation stimulated by HG and TNF-, reduces VCAM-1 and
ICAM-1 expression in parallel (supplemental Fig. 5, and sup-
plemental Fig. 6), but does not decrease the O-GlcNAc level
induced by HG (supplemental Fig. 7). Finally, the results that
azaserine protects against impaired endothelium-dependent re-
laxations caused by an acute exposure of the aortas to HG (5
h), whereby no changes in O-GlcNAc levels in the blood
vessels were observed, further support the antioxidant effect of
the GFAT inhibitor azaserine (Fig. 8). The antioxidative effect
of azaserine has been noted in cultured renal proximal tubular
cells (17). Moreover, the results with resveratrol suggest that
the inhibition of superoxide generation by resveratrol accounts
for the inhibition of endothelial adhesion molecule expression
stimulated by HG and TNF-. The results of our current study
do not support the hypothesis that hyperglycemia-induced
superoxide generation drives O-GlcNAc formation (12) but
rather suggest that hyperglycemia causes oxidative stress and
HBP ﬂux independently. The reason for the disparity remains
obscure at this stage.
One of the interesting ﬁndings is that the treatment of the
endothelial cells with azaserine is able to upregulate MnSOD
protein under the LG condition. HG alone does not affect the
MnSOD protein level, whereas TNF- is able to upregulate
MnSOD protein expression (Fig. 7), which may reﬂect the
insufﬁcient compensatory effect of the antioxidative system.
The upregulation of MnSOD by TNF- has been also reported
by other groups (35, 39). The upregulation of MnSOD by
TNF- is diminished under the HG condition. This could be
due to the exaggerated oxidative injury to the cells. Interest-
ingly, the downregulation of MnSOD by TNF- under the HG
condition is reversed by azaserine (Fig. 7), suggesting that the
antioxidative effect of azaserine may be attributed by the
upregulation of MnSOD. Moreover, the upregulation of MnSOD
is even observed after a short-time (1 h) treatment of the cells
with azaserine (supplemental Fig. 8), which is associated with
the inhibition of superoxide generation (supplemental Fig. 9).
Similar to the experiments in cultured cells, the treatment of
aortic rings ex vivo with azaserine also increases the MnSOD
protein level (Fig. 8C), which is associated with improved
endothelium-dependent relaxations (Fig. 8A). Whether the up-
regulation of MnSOD fully accounts for the antioxidative
effect of azaserine requires further investigation. The results
demonstrate at least an important mechanism of anti-oxidative
effect of azaserine in vascular cells.
In conclusion, hyperglycemia causes oxidative stress and
HBP ﬂux, ampliﬁes endothelial inﬂammation, and impairs
endothelial function mainly through oxidative stress and not
the HBP pathway. It emphasizes that the results do not exclude
the potential role of the HBP pathway in the inhibition of
insulin-mediated metabolic signalings in the insulin target
tissues and eNOS activation (5, 11, 13, 41). Our results
demonstrate that azaserine not only inhibits the HBP pathway
but is also a strong antioxidant. Azaserine prevents against
endothelial inﬂammation and the impairment of endothelium-
dependent relaxations under the hyperglycemic condition
through the inhibition of oxidant stress independently of the
inhibiting HBP pathway.
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